RBR-93gkd4
Recruiting
Phase 3
Efficacy and safety of Eslicarbazepine Acetate (BIA 2-093) as monotherapy for patients with newly diagnosed partial-onset seizures: a double-blind, randomized, active-controlled, parallel-group, multicenter clinical trial - open-label ESL extension
Instituto de Neurologia de Curitiba0 sitesMarch 11, 2016
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Epilepsy
- Sponsor
- Instituto de Neurologia de Curitiba
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participation in the preceding double\-blind study and still ongoing at the time of unblinding; informed consent signature; cooperation and willingness to complete all aspects of the study.
Exclusion Criteria
- •Exclusion from the double\-blind study; clinical evaluation of suicidal risk; occurrence of an adverse event; events of alcohol, drug, or medication abuse; relevant clinical laboratory abnormalities; pregnancy or lactating.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial SeizuresHealth Condition 1: null- Partial EpilepsyCTRI/2011/04/001686Bial Portela C SA615
Active, not recruiting
Phase 1
Eslicarbazepine Acetate (BIA 2-093) as Therapy for Refractory Partial Seizures in Childrechildren and adolescents with refractory partial epileptic seizuresMedDRA version: 14.0Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2007-001887-55-ATBIAL - Portela & Ca, S.A.315
Active, not recruiting
Phase 1
Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as monotherapy for patients with newly diagnosed partial-onset seizures - open label extension study with eslicarbazepine acetateAdult patients with recently diagnosed partial-onset seizuresMedDRA version: 21.1Level: LLTClassification code 10065336Term: Partial epilepsySystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2015-001243-36-ITBIAL-PORTELA & Cª, S.A.207
Active, not recruiting
Phase 1
Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in children: a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trialEUCTR2007-001887-55-GBBIAL - Portela & Ca, S.A.304
Active, not recruiting
Phase 1
Eslicarbazepine Acetate (BIA 2-093) as Therapy for Refractory Partial Seizures in Childrechildren and adolescents with refractory partial epileptic seizuresMedDRA version: 16.0Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2007-001887-55-CZBIAL - Portela & Ca, S.A.315